U.K.-based CatSci acquired Reach Separations, a specialist chromatography provider for the analysis and purification of chiral and achiral therapeutics. The acquisition was supported by Keensight Capital, a private equity manager which focuses on pan-European Growth Buyout investments.

The acquisition of Reach, headquartered in the U.K., and with laboratories in both the U.K. and France, will enable CatSci to offer its global customers access to holistic chromatographic services that will aid them from discovery through to manufacture, catering to full asset development or standalone projects, according to a CatSci official, who adds that this enhanced separation science offering will provide the analysis for small molecules, oligonucleotides, and other complex synthetic medicines.

Range of screening options

Reach’s supercritical fluid chromatography (SFC) and HPLC (high-performance liquid chromatography) instrumentation provides a range of screening options for its clients. This acquisition marks a significant milestone in CatSci’s growth strategy as the company continues to enhance its CMC (Chemistry, Manufacturing and Controls) capabilities to add strategic value to their partnerships with customers, notes Ross Burn, PhD, CEO, CatSci.

“The need for solving complex analytical problems while meeting the ever-evolving regulatory demands is growing alongside the development of new modalities, such as oligonucleotides, TACs (Targeting Chimeras), and glues,” says Ross. “Joining forces with Reach gives our customers access to end-to-end coverage of the analytical development lifecycle, taking them from discovery through to GMP manufacture, and ultimately enabling them to help patients in need.’’

“Integrating our technologies and expertise across the discovery and development landscape will provide a one-stop-shop for analysis and purification, giving the client a variety of options to progress the journey of their asset,” adds Peter Ridgway, business development director, Reach Separations.

Previous articleBertozzi’s TwoStep Therapeutics to Target Solid Tumors With Engineered Peptide Drug Delivery Vehicle
Next articlePET Radiotracer Pinpoints Active TB in Patients’ Lungs